Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22837883 | 0.85 | ADORA3 (0.37) | ADORA3ADORA2ASLC28A1 | |
| SCHEMBL22837934 | 0.78 | PDE4A (0.37) | ADORA3ADORA2A | |
| SCHEMBL22837902 | 0.77 | NPEPPS (0.33) | — | |
| SCHEMBL20711329 | 0.77 | ADORA3 (0.52) | ADORA3 | |
| SCHEMBL22837901 | 0.76 | AHCY (0.43) | — | |
| SCHEMBL22837920 | 0.75 | ADORA3 (0.35) | ADORA3ADORA2ASLC28A1 | |
| SCHEMBL20711308 | 0.75 | POLB (0.49) | — | |
| SCHEMBL22837900 | 0.75 | ADORA3 (0.36) | ADORA3ADORA2ASLC28A1 | |
| SCHEMBL20711215 | 0.74 | DPP4 (0.58) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL20711304 | 0.73 | BCHE (0.44) | PI4KAPI4K2BPI4K2API4KBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | ATIC, SLC35B2, ADORA1 | PI4KA 2340/4885PI4K2B 3618/4885PI4K2A 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.